Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia

Despite the successes achieved with molecular targeted inhibition of the oncogenic driver Bcr-Abl in chronic myeloid leukemia (CML), the majority of patients still require lifelong tyrosine kinase inhibitor (TKI) therapy. This is primarily caused by resisting leukemic stem cells (LSCs), which preven...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Leukemia
Asıl Yazarlar: Parting, Oliver, Langer, Samantha, Kuepper, Maja Kim, Wessling, Caroline, Li, Shaoguang, Braunschweig, Till, Chatain, Nicolas, Maié, Tiago, Costa, Ivan G., Crysandt, Martina, Huber, Michael, Brümmendorf, Tim H., Koschmieder, Steffen, Schemionek, Mirle
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515845/
https://ncbi.nlm.nih.gov/pubmed/32684632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0977-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller